This is a routine, small-dollar insider sale by a director following RSU vesting. No material signal for traders. Monitor for any larger insider sales or changes in ownership patterns ahead of upcoming catalysts.
XENE drugs
XENE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 8 $51.21entry
- T+1 · 5mo ago +3.09%α +3.38% · $52.79
- T+5 · 5mo ago +2.32%α +0.21% · $52.40
- T+20 · 4mo ago +18.22%α +16.59% · $60.54
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Gary Patou filed a Form 144 notice of intent to sell 1,322 shares of Xenon Pharmaceuticals common stock, valued at approximately $70,053 based on the filing date. This is a very small sale relative to the company's $5.1B market cap and appears to be a routine, low-conviction signal.
Key Facts
- Director Gary Patou filed Form 144 to sell 1,322 shares of XENE common stock.
- Estimated sale value is approximately $70,053 based on the filing date.
- The shares were acquired from restricted stock units vesting on 05/31/2026.
- The sale represents a tiny fraction of the company's $5.1B market cap.
- No other insider sales or purchases were reported in the prior 30 days.
Financial Impact
Sale of 1,322 shares worth ~$70,053; negligible relative to $5.1B market cap.
Risk Factors
- Insider sale intent is filed but may not be executed.
- No material risk to stock price from this filing alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-005710 |
| Document: 0001950047-26-005710-index.html | 0001950047-26-005710 |
| Document: 0001950047-26-005710.txt | 0001950047-26-005710 |
Track record
19 reports on XENE
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Viewing Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers